Testing effectiveness (Phase 2)Study completedNCT02197676
What this trial is testing
A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response
Who this might be right for
MDS
Groupe Francophone des Myelodysplasies 56